This filing is routine and does not reflect new operational or financial developments. Traders should monitor the company's next quarterly filing for updates on clinical trial progress or financing activities, as the current amendment provides no new business or financial data.
Price Chart
Executive Summary
Xenetic Biosciences filed an amended 10-K to include Part III disclosures (Items 10-14) on directors, executive compensation, and related-party transactions, which were initially omitted in reliance on proxy statement incorporation. The amendment includes updated director biographies, compensation details, and related-party agreements, but contains no financial restatements or material corrections.
Key Facts
- Amendment adds Part III disclosures (directors, executive compensation, related-party transactions) previously omitted from the original 10-K filing.
- No financial statements were amended or restated; the filing is administrative in nature.
- Key related-party transactions include a $0.4 million consulting agreement with board chairman Dr. Dmitry Genkin and a $0.2 million clinical trial agreement with Peri-Ness Ltd., where two directors hold significant ownership.
- The company paid $208,000 in audit and audit-related fees to CBIZ CPAs P.C. for fiscal year 2025.
- Insider ownership includes Dr. Genkin (9.4%) and institutional holder Renaissance Technologies (7.8%).
Financial Impact
No financial impact — this is a disclosure-only amendment with no restatements.
Risk Factors
- Related-party transactions with board members may raise governance concerns for some investors.
- High concentration of ownership among insiders and related parties could influence corporate decisions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001683168-26-003207 |
| Document: xenetic_ex3104.htm | 0001683168-26-003207 |
| Document: xenetic_ex3103.htm | 0001683168-26-003207 |
| Document: 0001683168-26-003207-index-headers.html | 0001683168-26-003207 |
| Document: 0001683168-26-003207-index.html | 0001683168-26-003207 |
| Document: 0001683168-26-003207.txt | 0001683168-26-003207 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 8-K | $2.47 $1.93 | ▼ −21.86% | ▼ −21.44% | $1.82 (−26.13%) |
Sep 18, 2026 5w ago | SC 13G | $2.77 $1.99 | ▼ −28.16% | ▼ −28.36% | $1.82 (−34.13%) |
Sep 16, 2026 5w ago | 8-K | $2.19 $2.10 | ▼ −4.11% | ▼ −7.29% | $1.82 (−16.68%) |
Aug 7, 2026 11w ago | 8-K | $3.17 $4.67 | ▲ +47.32% | ▲ +47.72% | $1.82 (−42.44%) |
May 13, 2026 23w ago | 8-K | $3.18 $3.00 | ▼ −5.66% | ▼ −5.05% | $1.82 (−42.62%) |
Apr 24, 2026 26w ago | 10-K/A | $3.03 $3.07 | ▲ +1.18% | ▼ −3.77% | $1.82 (−39.78%) |
Apr 24, 2026 26w ago | 8-K | $3.03 $3.07 | ▲ +1.18% | ▼ −3.77% | $1.82 (−39.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers